FindTrial
Sign In

Explore the association between genetic polymorphisms and clopidogrel efficacy for acute minor-moderate non-cardiogenic ischemic stroke (NIHSS score = 8) and high-risk transient ischemic attack (ABCD2 = 4) (PALACE): a prospective study based on real-world

Explore the association between genetic polymorphisms and clopidogrel efficacy for acute minor-moderate non-cardiogenic ischemic stroke (NIHSS score = 8) and high-risk transient ischemic attack (ABCD2 = 4) (PALACE): a prospective study based on real-world

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000038823
Enrollment
Unknown
Registered
2020-10-04
Start date
2020-10-01
Completion date
Unknown
Last updated
2022-01-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-cardiogenic ischaemic stroke

Interventions

case series:Nil

Sponsors

The First Hospital of Shanxi Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. With informed consent signed; 2. Acute ischemic stroke (diagnosed according to the AHA/ASA criteria) within 72 hours of symptom onset; 3. NIHSS score 8 but rapid remission or fluctuation; 5. TIA (ABCD2 >= 4).

Exclusion criteria

Exclusion criteria: 1. mRs >= 2; 2. Cardiogenic ischemic stroke; 3. Intracranial hemorrhagic disease; 4. With severe cardiopulmonary disease, the researchers think it is unsuitable to participate in this study; 5. Patients with a life expectancy of < 3 months and unable to complete the study; 6. Patients who were recruited in other trials.

Design outcomes

Primary

MeasureTime frame
new clinical compound ischemic vascular events;—

Secondary

MeasureTime frame
all course death;—

Countries

China

Contacts

Public ContactLiu Tingting

The First Hospital of Shanxi Medical University

liutin_2000@126.com+86 13546716109

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026